Vanda Pharmaceuticals (NASDAQ:VNDA) Now Covered by Analysts at StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a research report issued to clients and investors on Wednesday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright initiated coverage on Vanda Pharmaceuticals in a research note on Thursday, October 31st. They issued a “buy” rating and a $18.00 price objective on the stock.

Vanda Pharmaceuticals Stock Performance

NASDAQ:VNDA opened at $4.60 on Wednesday. The stock has a market cap of $268.22 million, a price-to-earnings ratio of -16.43 and a beta of 0.76. Vanda Pharmaceuticals has a 1 year low of $3.46 and a 1 year high of $6.75. The business has a fifty day moving average of $4.84 and a 200-day moving average of $5.24.

Insider Buying and Selling at Vanda Pharmaceuticals

In other news, Director Stephen Ray Mitchell sold 5,000 shares of Vanda Pharmaceuticals stock in a transaction that occurred on Thursday, November 14th. The shares were sold at an average price of $5.17, for a total value of $25,850.00. Following the transaction, the director now directly owns 44,857 shares of the company’s stock, valued at $231,910.69. This trade represents a 10.03 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 8.90% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Vanda Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Meeder Asset Management Inc. acquired a new stake in Vanda Pharmaceuticals during the 2nd quarter valued at $39,000. ORG Wealth Partners LLC purchased a new position in shares of Vanda Pharmaceuticals during the third quarter valued at $40,000. China Universal Asset Management Co. Ltd. grew its holdings in shares of Vanda Pharmaceuticals by 64.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 11,211 shares of the biopharmaceutical company’s stock valued at $53,000 after buying an additional 4,374 shares in the last quarter. SG Americas Securities LLC acquired a new position in Vanda Pharmaceuticals during the second quarter valued at $61,000. Finally, Price T Rowe Associates Inc. MD lifted its stake in Vanda Pharmaceuticals by 18.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 15,824 shares of the biopharmaceutical company’s stock worth $66,000 after acquiring an additional 2,425 shares in the last quarter. Institutional investors and hedge funds own 88.14% of the company’s stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.